Viz.ai Receives FDA 510(k) Clearance for Viz SUBDURAL (SDH)

AI-powered Viz SUBDURAL (SDH) automatically detects subdural hemorrhage, enables effective triage and optimal careSAN FRANCISCO - July 27, 2022 - Viz.ai, the leading AI-powered disease detection and intelligent care coordination platform, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Viz Subdural (SDH). The Viz SDH algorithm uses artificial intelligence to automatically detect subdural hemorrhage, enabling physicians to triage patients effectively and deliver optimal care. However, acute and chronic subdural hemorrhages require different types of intervention via different clinical pathways, with some requiring quick attention from the care team. “Viz SDH allows us to detect both acute and chronic subdural hemorrhages to better identify early treatment pathways. “Subdural hemorrhages are growing in commonality, but can present different levels of urgency with different clinical pathways.